Biofrontera AG Says Plans Capital Reduction And Considers Subsequent Capital Increase From Authorized Capital
Biofrontera AG 
B8F:
PLANS CAPITAL REDUCTION AND CONSIDERS SUBSEQUENT CAPITAL INCREASE FROM AUTHORIZED CAPITAL
CONSIDERING TO CARRY OUT A CAPITAL INCREASE RELATIVELY SOON AFTER CAPITAL REDUCTION BECOMES EFFECTIVE
ORDINARY CAPITAL REDUCTION BY CONSOLIDATING EXISTING NO-PAR VALUE SHARES AT A RATIO OF 21:1
CAPITAL REDUCTION WILL ALSO ENSURE THAT COMPANY'S SHARE PRICE RISES SIGNIFICANTLY ABOVE EUR 1.00 AGAIN
AS A RESULT, NEW SHARE CAPITAL IS TO AMOUNT TO ABOUT EUR 3 MILLION
CAPITAL REDUCTION SERVES TO OFFSET ACCUMULATED LOSSES AND THOSE EXPECTED IN CURRENT FINANCIAL YEAR 2024.
IN ORDER TO MAKE THIS RATIO POSSIBLE, SEVEN SHARES PROVIDED TO COMPANY FREE OF CHARGE BY A SHAREHOLDER ARE TO BE WITHDRAWN BEFOREHAND